CN104758309A - Application of strawberry polysaccharide in reduction of blood sugar - Google Patents
Application of strawberry polysaccharide in reduction of blood sugar Download PDFInfo
- Publication number
- CN104758309A CN104758309A CN201510169399.0A CN201510169399A CN104758309A CN 104758309 A CN104758309 A CN 104758309A CN 201510169399 A CN201510169399 A CN 201510169399A CN 104758309 A CN104758309 A CN 104758309A
- Authority
- CN
- China
- Prior art keywords
- polysaccharide
- fructus rubi
- food
- health product
- purposes according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Abstract
The invention provides an application of strawberry polysaccharide in preparation of medicines, health goods or foods for reducing blood sugar. The research shows that the strawberry polysaccharide has excellent functions of reducing blood sugar and blood fat, is few in toxic and side effects, and has significant social value and market value.
Description
Technical field
The invention belongs to field of health care products, be specifically related to Fructus Rubi polysaccharide and preparing the purposes in hypoglycemic drug.
Technical background
According to statistics, the number of patients of current China diabetes has reached 9,240 ten thousand, occupies (Yang W, et al.NEngl J Med, 2010,362 (12): 1090-1101) first of the whole world.Diabetes mellitus in China medical expense is every year up to 1,734 hundred million yuan, and the direct medical expenses caused by diabetes has accounted for 13% (Alcorn T, et al.Lancet, 2012,379 (9833): 2227-2228) of Chinese medical total expenses.As can be seen here, the health of the diabetes not only serious harm people, and bring heavy financial burden for country.Thus, diabetes are prevented and treated very urgent.
Fructus Rubi (Rubus idaeus L.) has another name called Rubus corchorifolius Linn. f., Fructus Rubi corchorifolii Immaturus, Fructus Rubi etc., belongs to Rosaceae rubus.Fructus Rubi is mainly distributed in temperate zone, the Northern Hemisphere and frigid zone, and its fruit is the little aggregate fruit of many slurries, the sweet micro-acid of taste.Fructus Rubi contains polysaccharide, organic acid, flavone, anthocyanidin, and the various active compositions such as polyphenol, vitamin, mineral element, volatile oil, tannin, have high nutritive value and medical care effect, be described as " gold fruit ".
Yet there are no the report using Fructus Rubi polysaccharide for reducing blood sugar or treatment diabetes.
Summary of the invention
The object of the present invention is to provide the novelty teabag of Fructus Rubi polysaccharide.
Particularly, the invention provides the purposes of Fructus Rubi polysaccharide in preparation hypoglycemic medicine, health product or food.
Further, described medicine, health product or food are prevention or the medicine for the treatment of I type or type ii diabetes, health product or food.
Further, described medicine, health product or food improve the medicine of dyslipidemia in diabetes, health product or food.
Further, described medicine, health product or food reduce diabetics TC, TG and LDL level, improves the medicine of HDL level, health product or food.
Wherein, described medicine, health product or food are peroral dosage form.
Further, described peroral dosage form is selected from tablet, capsule, pill, granule, powder, extractum or oral liquid.
Wherein, in described Fructus Rubi polysaccharide, purity of polysaccharide is more than 50%; Further, purity of polysaccharide is more than 80%; Further, purity of polysaccharide is more than 85%; Preferably, purity of polysaccharide is 85 ~ 95%w/w, if moderate purity of the present invention is 90 ~ 92%.Above-mentioned purity adopts Phenol-sulphate acid method to measure.
Wherein, described Fructus Rubi polysaccharide adopts decoction and alcohol sedimentation technique to prepare.
Further, described decoction and alcohol sedimentation technique concrete operations are as follows:
Get dry Fructus Rubi, after petroleum ether or ether defatting, with concentration 75% ~ more than 95%v/v ethanol extraction, filter, filtering residue extracting in water, after water intaking extract is concentrated, adds ethanol and reach 75% ~ 85% to alcohol content, cooling, to leave standstill, get solid content and be Fructus Rubi polysaccharide.
Wherein, Fructus Rubi removes seed or does not remove seed before extracting.
Wherein, in precipitate with ethanol process, add ethanol and reach 75% to alcohol content.
Wherein, described Fructus Rubi is the fruit of Rosaceae rubus.
Further, described Fructus Rubi is selected from red raspberry or black raspberry, choice for use red raspberry in the present invention's detailed description of the invention.
The present invention studies discovery, and Fructus Rubi polysaccharide has good blood sugar lowering and hypolipemic function, and toxic and side effects is little, has significant social value and market value.
Accompanying drawing illustrates:
Accompanying drawing 1 Fructus Rubi polysaccharide causes the impact of diabetes rat body weight on STZ;
Accompanying drawing 2 Fructus Rubi polysaccharide causes the impact of blood glucose in diabetic rats on STZ;
Detailed description of the invention
The Fructus Rubi polysaccharide used in the specific embodiment of the invention adopts conventional Polyose extraction, way of purification prepares, and concrete operations are as follows in the present invention:
Prepared by Fructus Rubi polysaccharide: get dry Fructus Rubi, after seed is removed in pulverizing, add 5 times of petroleum ether (boiling range 60 ~ 90 DEG C) defat, 75% ~ 95% ethanol is added in 60 DEG C of backflows after eliminating petroleum ether, filtering residue after filtering is added 10 times of pure water supersound extraction (power 60W, temperature: 80 DEG C, processing time: 100min), centrifuging and taking supernatant, filtering residue extracts twice again by old terms, merging filtrate, be evaporated to 1/4 of original volume, add 95% ethanol, solution alcohol content is made to reach 75%v/v, in 4 degrees Celsius of standing 24h, collecting by filtration filtering residue, filtering residue dries to obtain Fructus Rubi polysaccharide.
After measured, Fructus Rubi polysaccharide yield prepared by the present invention is 10.4% ~ 11.6%, and obtaining purity of polysaccharide through Phenol-sulphate acid method detection is 90.8% ~ 91.2%.
In various embodiments of the present invention, polysaccharide dosage used is all in polysaccharide.
Embodiment 1
The rat diabetes model that the present invention utilizes streptozotocin (STZ) to induce is to the effect of the blood sugar lowering and blood fat reducing of evaluating Fructus Rubi polyoses capsule main component Fructus Rubi polysaccharide.
Model process of establishing is as follows: before modeling, rat tail vein is got blood and surveyed blood glucose, weighs.Fasting afterwards 12 hours, by concentration disposable celiac injection STZ (being dissolved in the citrate buffer of the 0.1mol/L of pH4.2, matching while using under lucifuge condition) of 60mg/kg under rat limosis state.After 96 hours, tail venous blood sampling surveys blood glucose, and namely blood glucose value >=16.7mmol/L thinks that Glycemia Decline is successful.Successful for modeling rat is divided into 5 groups at random, and often organizing 10, is dosage combination Fructus Rubi polysaccharide high dose group in model group, positive controls, Fructus Rubi polysaccharide low dose group, Fructus Rubi polysaccharide respectively.Separately get 10 with batch healthy rat as Normal group.Rat grouping was weighed and gastric infusion the same day, and dosage is as follows: Normal group: pure water; Model group: pure water; Positive drug group: Glibenclamide Tablets 20mg/kg; Fructus Rubi polysaccharide basic, normal, high group of dosage is respectively: 75mg/kg, 150mg/kg, 300mg/kg.Successive administration 28 days, measures blood glucose and weighs for every 7 days.
(1) Fructus Rubi polysaccharide causes the impact of the basic sign of diabetes rat on STZ
Table 1. Fructus Rubi polysaccharide causes the impact of diabetes rat body weight on STZ
*p < 0.05vs model group;
*p < 0.01vs model group;
##p < 0.01vs normal group
As table 1 and Fig. 1, the body weight compared with normal rat respectively organizing diabetes rat after modeling all extremely significantly declines (
##p < 0.01vs normal group), the humidity of bedding and padding compared with normal rat, meets the basic sign of diabetes.The hair color of normal rats is glossy, and bedding and padding are dry, body weight steady-state growth.The hair color of model group rats is withered, slightly loses hair or feathers, and bedding and padding are moist, increases weight loss in time obvious.Comparatively model group is good for the hair color of each administration group rat, bedding and padding moisture conditions comparatively model group alleviates to some extent, though increase average weight with administration time have certain decline, downward trend is milder than model group, wherein the body weight measured for the last time of positive controls rat comparatively model group have significant difference (
*p < 0.05vs model group), the body weight measured for the last time of Fructus Rubi polysaccharide each dosage group rat comparatively model group have pole significant difference (
*p < 0.05vs model group).Compared with positive drug glibenclamide, Fructus Rubi polysaccharide can more effectively prevent alleviating of diabetes rat body weight.
(2) Fructus Rubi polysaccharide causes the impact of blood glucose in diabetic rats on STZ
Table 2. Fructus Rubi polysaccharide causes the impact of blood glucose in diabetic rats on STZ
*p < 0.01vs model group;
##p < 0.01vs normal group
As shown in table 2 and Fig. 2, after modeling, the blood glucose of normal rats without significant change, each group blood glucose in diabetic rats compared with normal rat all extremely significantly raises (
##p < 0.01vs normal group) after treatment, the blood glucose of each administration group rat comparatively model group all have pole significance decline (
*p < 0.01vs model group), and the hypoglycemic activity of Fructus Rubi polysaccharide is dose dependent.The average blood sugar value that Fructus Rubi polysaccharide high dose group rat is measured for the last time is 17.84 ± 1.41mmol/L, than positive controls rat measure for the last time average blood sugar 18.87 ± 2.22 also low.
(3) Fructus Rubi polysaccharide causes the impact of T-CHOL (TC) in diabetes rat serum, triglyceride (TG), high density lipoprotein (HDL) and low density lipoprotein, LDL (LDL) on STZ
Test the 28th day, after rats by intraperitoneal injection chloral hydrate solution general anesthesia, be separated common carotid artery and intubate collection blood.After blood coagulation, 3000r/min obtains serum sample in centrifugal 10 minutes.
Table 3. Fructus Rubi polysaccharide causes the impact of diabetes rat blood fat on STZ
*p < 0.01vs model group;
##p < 0.01vs normal group
As shown in table 3, compared with normal group, TC, TG and LDL in model group rats serum all increase extremely significantly, HDL declines extremely significantly (
##p < 0.01vs normal group).After treatment, compared with model group, TC, TG and LDL in each treatment group rat blood serum all decline extremely significantly, HDL increases extremely significantly (
*p < 0.01vs model group).Wherein, the effect of the blood fat reducing of Fructus Rubi polysaccharide is strengthened with the increase of dosage.The lipid-lowering effect of the middle and high dosage group of Fructus Rubi polysaccharide is even better than positive control drug Glibenclamide Tablets.
Claims (10)
1. the purposes of Fructus Rubi polysaccharide in preparation hypoglycemic medicine, health product or food.
2. purposes according to claim 1, is characterized in that: described medicine, health product or food are prevention or the medicine for the treatment of I type or type ii diabetes, health product or food.
3. purposes according to claim 1 and 2, is characterized in that: described medicine, health product or food improve the medicine of dyslipidemia in diabetes, health product or food; Further, described medicine, health product or food reduce diabetics TC, TG and LDL level, improves the medicine of HDL level, health product or food.
4. the purposes according to claims 1 to 3 any one, is characterized in that: described medicine, health product or food are peroral dosage form; Further, described peroral dosage form is selected from tablet, capsule, pill, granule, powder, extractum or oral liquid.
5. purposes according to claim 1, is characterized in that: in described Fructus Rubi polysaccharide, purity of polysaccharide is more than 50%; Further, purity of polysaccharide is more than 80%; Further, purity of polysaccharide is more than 85%; Preferably, purity of polysaccharide is 85 ~ 95%w/w.
6. the purposes according to Claims 1 to 5 any one, is characterized in that: described Fructus Rubi polysaccharide adopts decoction and alcohol sedimentation technique to prepare.
7. purposes according to claim 6, is characterized in that: described decoction and alcohol sedimentation technique concrete operations are as follows:
Get dry Fructus Rubi, after petroleum ether or ether defatting, with concentration 75% ~ 95%v/v ethanol extraction, filter, filtering residue extracting in water, after water intaking extract is concentrated, adds ethanol and reach 75% ~ 85% to alcohol content, cooling, to leave standstill, get solid content and be Fructus Rubi polysaccharide.
8. purposes according to claim 7, is characterized in that: Fructus Rubi removes seed or do not remove seed before extracting.
9. the purposes according to claim 1 ~ 9 any one, is characterized in that: described Fructus Rubi is the fruit of Rosaceae rubus.
10. the purposes according to claim 1 ~ 9 any one, is characterized in that: described Fructus Rubi is selected from red raspberry or black raspberry.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510169399.0A CN104758309B (en) | 2015-04-04 | 2015-04-04 | The purposes of raspberry polysaccharide for reducing blood sugar |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510169399.0A CN104758309B (en) | 2015-04-04 | 2015-04-04 | The purposes of raspberry polysaccharide for reducing blood sugar |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104758309A true CN104758309A (en) | 2015-07-08 |
| CN104758309B CN104758309B (en) | 2018-02-27 |
Family
ID=53640639
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510169399.0A Active CN104758309B (en) | 2015-04-04 | 2015-04-04 | The purposes of raspberry polysaccharide for reducing blood sugar |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104758309B (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104940427A (en) * | 2015-07-20 | 2015-09-30 | 德令哈林生生物科技开发有限公司 | Blood sugar reducing composition containing fructus lycii and application and preparing method thereof |
| CN111227253A (en) * | 2020-01-20 | 2020-06-05 | 江苏惠田科技开发有限公司 | Blackberry polysaccharide composite breakfast powder and preparation method thereof |
| CN112521521A (en) * | 2020-12-09 | 2021-03-19 | 青海大学 | Polysaccharide SM-W and anti-tumor product prepared from same |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1788755A (en) * | 2004-12-14 | 2006-06-21 | 北京市农林科学院 | Framberry leaf extract effective part and its composition and uses |
-
2015
- 2015-04-04 CN CN201510169399.0A patent/CN104758309B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1788755A (en) * | 2004-12-14 | 2006-06-21 | 北京市农林科学院 | Framberry leaf extract effective part and its composition and uses |
Non-Patent Citations (4)
| Title |
|---|
| 刘明学等: "覆盆子多糖提取、结构分析及自由基清除作用研究", 《食品科技》 * |
| 洪振丰等: "粗叶悬钩子根部提取物对急性肝损伤大鼠TNF-α IL-1β IL-6的影响", 《中华中医药学刊》 * |
| 王敏等: "树莓液对糖尿病模型大鼠血糖、胰岛素水平影响的实验研究", 《中医药信息》 * |
| 韩加等: "悬钩子属植物生物学作用研究进展", 《中国野生植物资源》 * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104940427A (en) * | 2015-07-20 | 2015-09-30 | 德令哈林生生物科技开发有限公司 | Blood sugar reducing composition containing fructus lycii and application and preparing method thereof |
| CN104940427B (en) * | 2015-07-20 | 2020-03-31 | 德令哈林生生物科技开发有限公司 | Blood sugar reducing composition containing wolfberry fruits and application and preparation method thereof |
| CN111227253A (en) * | 2020-01-20 | 2020-06-05 | 江苏惠田科技开发有限公司 | Blackberry polysaccharide composite breakfast powder and preparation method thereof |
| CN112521521A (en) * | 2020-12-09 | 2021-03-19 | 青海大学 | Polysaccharide SM-W and anti-tumor product prepared from same |
| CN112521521B (en) * | 2020-12-09 | 2021-11-05 | 青海大学 | Polysaccharide SM-W and anti-tumor product prepared from same |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104758309B (en) | 2018-02-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104083476A (en) | Application of rose extract in preparing anti-depression medicaments | |
| CN104383315A (en) | Chinese herbal medicinal composition for protecting liver and sobering and drink containing Chinese herbal medicinal composition | |
| CN104431064A (en) | Blood glucose-lowering tea and preparation method thereof | |
| CN104997883A (en) | Inonotus obliquus raspberry tree red raspberry composition, inonotus obliquus raspberry tree red raspberry composite oral solution and preparation method and application thereof | |
| CN105218695A (en) | A kind of lycium ruthenicum polysaccharide extract and preparation method thereof | |
| CN105341893A (en) | Composition for assisting in reducing blood glucose and application | |
| CN104758309A (en) | Application of strawberry polysaccharide in reduction of blood sugar | |
| CN104800174B (en) | A kind of raspberry polysaccharide buccal tablet and application thereof | |
| CN103301205A (en) | Refined glossy privet fruit total glycosides capable of preventing and treating liver injury, preparation method and application thereof | |
| KR101501233B1 (en) | Pharmaceutical composition or health food containing black tea ethanol solution extracts which is effective for reducing body weight and body fats or preventing or treating lipid related metabolic disease | |
| CN108651786A (en) | A kind of preparation method of full nutritional sea buckthorn fruit juice | |
| KR20150036538A (en) | Application of gynura divaricata in preparing medicine or health food for treating hepatitis | |
| CN104814975A (en) | Anti-fatigue uses of rubus idaeus polysaccharides | |
| KR101407889B1 (en) | Fraxinus rhynchophylla Hance extracts compositions for treating or preventing inflammatory diseases | |
| CN105218694A (en) | A kind of Lycium barbarum polysaccharide extract and preparation method thereof | |
| CN105012826A (en) | Alpinia oxyphylla leaf extract and preparation method and application thereof | |
| CN105434575B (en) | Application of Russian leaves and extract thereof in preparation of liver-protecting medicines or health-care foods | |
| KR20150077794A (en) | Anti-obesity composition comprising herbal extracts as an active ingredient | |
| JP2004352626A (en) | Anticholesterol agent containing plant-derived component | |
| CN106928376A (en) | The separation method of skunk bush polysaccharide and its application | |
| KR20140032961A (en) | Composition for preventing and treating diabetes and diabetes complications comprising amphicarpaea edgeworthii var. trisperma powder or an extract thereof | |
| CN102120000B (en) | Composition of effective parts of traditional Chinese medicine preparation for resisting Coxsackie virus B and preparation method thereof | |
| CN104825387A (en) | Raspberry polysaccharide oral solution and application thereof | |
| CN104758270A (en) | Strawberry polysaccharide effervescent tablet and application thereof | |
| CN110742969A (en) | Preparation method of composition for improving sleep disorder caused by kidney yin deficiency |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| EXSB | Decision made by sipo to initiate substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20230918 Address after: Room 1218-19, Building 3, No. 1366 Hongfeng Road, Huzhou Economic and Technological Development Zone, Huzhou City, Zhejiang Province, 313098 Patentee after: Zhonghe baosang Biotechnology Co.,Ltd. Address before: 810001 No. 59 Xiguan Street, Xining, Qinghai Patentee before: Northwest Institute of Plateau Biology, Chinese Academy of Sciences |
|
| TR01 | Transfer of patent right |